Drugs in Treating Urinary Schistosomiasis
Urinary schistosomiasis caused by trematodes of the genus Schistosoma known as Schistosoma haematobium. Schistosoma haematobium, also known to be “urinary blood fluke” that inhabits and multiplies eggs in the small venules of the perivesical and portal systems. Urinary schistosomiasis is endemic in 53 countries in Africa and the Middle East. A cholinesterase inhibitor Metrifonate is another selective treatment for SH; it has good efficacy and safety properties. Although it is economic, causes low recurrence rates. Metrifonate is that a prophylactic dose which is needed within two years to guard against recurrence. Niridazole is also highly effective for treating schistosomiasis, and a single dose of niridazole daily has a high cure rate.
- In vitro studies
- Albendazole Treatment
- Egg Reduction Rate
Related Conference of Drugs in Treating Urinary Schistosomiasis
7th World Congress on Neuroimmunology and Neuroinfectious Diseases
22nd International Conference on Allergic Diseases and Clinical Immunology
14th World Congress and Exhibition on Antibiotics and Antibiotic Resistance
Drugs in Treating Urinary Schistosomiasis Conference Speakers
Recommended Sessions
Related Journals
Are you interested in
- Advances in Neuroimaging and Diagnostic Techniques - Neuroimmunology Congress 2026 (France)
- Advances in Neuroimmunology and Neuroinflammation - Neuroimmunology Congress 2026 (France)
- Artificial Intelligence and Data-Driven Approaches in Neuroimmunology - Neuroimmunology Congress 2026 (France)
- Autoimmune Neurological Disorders and Therapeutic Advances - Neuroimmunology Congress 2026 (France)
- Biomarkers and Precision Medicine in Neuroimmune Disorders - Neuroimmunology Congress 2026 (France)
- Case Studies and Clinical Practice in Neuroimmunology and Neuroinfectious Diseases - Neuroimmunology Congress 2026 (France)
- Clinical Trials and Drug Development in Neuroimmunology - Neuroimmunology Congress 2026 (France)
- CNS Infections: Diagnosis, Management, and Prevention - Neuroimmunology Congress 2026 (France)
- Emerging Technologies and Future Directions in Neuroimmunology - Neuroimmunology Congress 2026 (France)
- Ethical Considerations and Future Perspectives in Neuroimmunology Research - Neuroimmunology Congress 2026 (France)
- Immunogenetics and Neuroimmune Interactions - Neuroimmunology Congress 2026 (France)
- Immunotherapy and Novel Treatment Strategies - Neuroimmunology Congress 2026 (France)
- Microbiome and the Gut-Brain-Immune Axis - Neuroimmunology Congress 2026 (France)
- Neurodegeneration and Immune System Interactions - Neuroimmunology Congress 2026 (France)
- Neuroimmunology in Pediatric Disorders - Neuroimmunology Congress 2026 (France)
- Neuroinfectious Diseases and Global Health Challenges - Neuroimmunology Congress 2026 (France)
- Public Health, Policy, and Global Collaboration in Neuroimmunology - Neuroimmunology Congress 2026 (France)
- Rehabilitation and Long-Term Management of Neuroimmune Disorders - Neuroimmunology Congress 2026 (France)
- Translational Research and Clinical Applications in Neuroimmunology - Neuroimmunology Congress 2026 (France)
- Young Researchers, Innovation, and Emerging Ideas - Neuroimmunology Congress 2026 (France)

